Showing results (261-270 of 3,316) with videos related to
Sort By:
Pageof 332
Journal of Clinical Psychopharmacology|December 6, 2016
Cognitive Impairment and Tramadol DependenceMedhat M Bassiony, Usama M Youssef, Mervat S Hassan, et al.Journal of Clinical Psychopharmacology|November 3, 2016
Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Women With Schizophrenia: A Randomized Controlled TrialSui Cheung Man, Xian-Bin Li, Huai-Hai Wang, et al.Journal of Clinical Psychopharmacology|November 3, 2016
Anterior Cingulate Glutamate Is Reduced by Acamprosate Treatment in Patients With Alcohol DependenceMark A Frye, David J Hinton, Victor M Karpyak, et al.Journal of Clinical Psychopharmacology|November 3, 2016
Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine: Human Model to Assess Central and Peripheral Effects of DosingPeter R Bieck, Mark Leibowitz, D Richard Lachno, et al.Journal of Clinical Psychopharmacology|December 28, 2016
A Validation Study of the International Consensus Diagnostic Criteria for Neuroleptic Malignant SyndromeRonald J Gurrera, Gino Mortillaro, Varadaraj Velamoor, et al.Journal of Clinical Psychopharmacology|April 11, 2014
The effects of armodafinil on objective sleepiness and performance in a shift work disorder sample unselected for objective sleepinessRyan Howard, Thomas Roth, Christopher L DrakeJournal of Clinical Psychopharmacology|February 15, 2014
Methylphenidate enhances cognitive performance in adults with poor baseline capacities regardless of attention-deficit/hyperactivity disorder diagnosisNirit Agay, Eldad Yechiam, Ziv Carmel, et al.Journal of Clinical Psychopharmacology|February 15, 2014
The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trialJoep H Schoemaker, Wim T Jansen, Jacques Schipper, et al.Journal of Clinical Psychopharmacology|January 28, 2017
Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label StudyEun-Jin Cheon, Kwang-Hun Lee, Young-Woo Park, et al.Journal of Clinical Psychopharmacology|December 9, 2016
Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic StudyMahyar Etminan, Mohit Sodhi, Ali Samii, et al.Pageof 332